Physician profile
Jason P Kellogg
NPI 1952331530
$2,722,584.00
in general payments reported to CMS, 2019-2025
35 companies · $463K in 2025
The $463K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585K · 2020: $198K · 2021: $253K · 2022: $363K · 2023: $429K · 2024: $432K · 2025: $463K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Travel and Lodging: $196K · Consulting Fee: $57K · Food and Beverage: $33K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,037,604.03 |
| Travel and Lodging | $196,436.42 |
| Consulting Fee | $56,747.00 |
| Food and Beverage | $33,441.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $582,794.52 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $577,271.78 | 2019-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $407,260.84 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $241,914.35 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $214,381.42 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196,930.23 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $131,128.13 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $118,052.53 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $92,067.82 | 2019-2025 | Lybalvi, Aristada |
| Allergan, INC. | $64,547.45 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $37,282.26 | 2019-2022 | |
| Indivior INC. | $36,822.76 | 2019-2024 | Perseris |
| Sage Therapeutics, LLC | $6,838.02 | 2019-2022 | |
| Abbvie INC. | $6,213.48 | 2021-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,439.40 | 2019-2025 | Rejoyn |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $2,361.33 | 2022-2024 | Auvelity |
| Biogen, INC. | $1,623.08 | 2022-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $1,503.40 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $214.20 | 2019-2020 | |
| Livanova USA, INC. | $205.55 | 2020-2021 | |
| Eisai INC. | $169.80 | 2020-2021 | |
| Luye Pharma (USA) Ltd. | $167.38 | 2025 | Erzofri Extended-Release |
| Lundbeck LLC | $121.15 | 2019-2025 | Rexulti |
| Adlon Therapeutics L.P. | $70.46 | 2021 | |
| Sun Pharmaceutical Industries INC. | $41.22 | 2021 | |
| Bausch Health US, LLC | $37.11 | 2021-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $24.55 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.21 | 2022 | |
| Mdd US Operations, LLC | $20.35 | 2019 | |
| Corium, LLC | $18.99 | 2024 | Azstarys |
| Vertical Pharmaceuticals, LLC | $14.82 | 2024 | Relexxii |
| Merck Sharp & Dohme LLC | $13.61 | 2020 | |
| Brainsway USA INC | $7.80 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.